Rho®

Welcome to a different kind of CRO.

Bringing your product to market takes something different.

At Rho, we're experienced, creative problem-solvers who provide outstanding clinical research fueled by our unique team approach. Our dedication to collaboration makes your clinical trials and programs run smarter and more efficiently.

How do we do that?

Commitment, loyalty and stability of our teams

- Low turnover rate – consistently less than half of industry standard
- The long tenure of many of our employees allows us to provide consistent, stable teams
- 90%+ of our staff work from our headquarters in NC, for stronger teams, better communication and seamless handoffs

MORE THAN 50%
of our team have been at Rho for **5 years or more**

PLs AVERAGE 6 YEARS at Rho
and **11 years in the industry**

Experienced project leaders

- Two out of three have advanced degrees
- CRAs average three years at Rho, 13 years in industry and 11 years of CRA experience

Industry leader

- Expertise in creation and application of data standards (CDISC) and NDA submissions
- Leaders in project/program rescues
- Understand individual studies in the context of development program goals
- Efficient and effective marketing application submission strategy

MORE THAN
300
PUBLICATIONS
in more than 96 journals,
including The Lancet, Nature and NEJM

79%
of clients surveyed rated Rho
SUPERIOR OR VERY SUPERIOR
compared to other CROs

Size, stability and a focus

- In business for 30+ years
- Privately held; strategic financial outlook; no debt
- Personal attention; C-level access
- Project-focused organization
- Transparent, predictable costs

IND – Phase IV

IND | PHASE I | PHASE II | PHASE III | NDA | PHASE IV

Rho offers full end-to-end services for your entire drug development program.

- Pre-trial regulatory guidance
- Pre-IND briefing packages
- IND applications/annual updates
- Protocol development
- Clinical operations
- Regulatory document strategy
- Clinical data management
- SAE management & narratives
- Clinical project management
- Statistical analysis
- IVR/IWR
- DSMB reports
- Clinical study reports
- Data standards
- New drug applications
- Biologic license applications
- 510(K) submissions